William Blair Analysts Raise Earnings Estimates for aTyr Pharma, Inc. (LIFE)

aTyr Pharma, Inc. (NASDAQ:LIFE) – Stock analysts at William Blair boosted their Q1 2018 earnings estimates for aTyr Pharma in a research report issued to clients and investors on Tuesday. William Blair analyst Y. Xu now forecasts that the biotechnology company will post earnings of ($0.48) per share for the quarter, up from their previous estimate of ($0.53). William Blair also issued estimates for aTyr Pharma’s Q2 2018 earnings at ($0.48) EPS, Q3 2018 earnings at ($0.48) EPS, Q4 2018 earnings at ($0.47) EPS and FY2018 earnings at ($1.91) EPS.

aTyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.43) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.07.

Other research analysts have also recently issued reports about the stock. Zacks Investment Research upgraded shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a report on Saturday, November 18th. ValuEngine cut shares of aTyr Pharma from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $4.81.

aTyr Pharma (NASDAQ:LIFE) opened at $3.35 on Thursday. The company has a current ratio of 9.49, a quick ratio of 9.49 and a debt-to-equity ratio of 0.17. aTyr Pharma has a 1-year low of $2.30 and a 1-year high of $6.50.

A number of institutional investors have recently modified their holdings of the business. Dimensional Fund Advisors LP grew its holdings in aTyr Pharma by 44.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock worth $423,000 after acquiring an additional 25,676 shares in the last quarter. Victory Capital Management Inc. bought a new position in aTyr Pharma during the 3rd quarter worth about $455,000. Finally, Artal Group S.A. grew its holdings in aTyr Pharma by 100.0% during the 4th quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock worth $1,750,000 after acquiring an additional 250,000 shares in the last quarter. Institutional investors own 58.30% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://sportsperspectives.com/2018/02/10/william-blair-analysts-raise-earnings-estimates-for-atyr-pharma-inc-life.html.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply